David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA.
Trends Biotechnol. 2014 Sep;32(9):466-73. doi: 10.1016/j.tibtech.2014.05.001. Epub 2014 Jun 12.
Here, we discuss recent advances in the development of artificial red blood cell (RBC) substitutes, illustrating lessons learned from initial attempts using perfluorocarbon (PFC) emulsions and acellular hemoglobin-based oxygen carriers (HBOCs). We also highlight novel oxygen-containing microparticles, nanoparticles, and stem cell-derived RBC products, with emphasis on improvements in biocompatibility and oxygen delivery. In addition, we envision future developments for the rational design of advanced blood substitutes that aim to address unmet clinical needs.
在这里，我们讨论了人工红细胞（RBC）代用品的最新进展，阐述了从最初使用全氟碳（PFC）乳剂和无细胞血红蛋白基氧载体（HBOCs）的尝试中吸取的经验教训。我们还重点介绍了新型含氧微粒、纳米颗粒和干细胞衍生的 RBC 产品，强调了提高生物相容性和氧传递的改进。此外，我们设想了用于合理设计高级血液代用品的未来发展，旨在满足未满足的临床需求。
